Merck to Buy Silence Therapeutics for $1.3 Billion in RNA
Merck agreed to buy Silence Therapeutics for $1.3B, a 130% premium over its previous closing price. The deal gives Merck access to Silence's siRNA-based treatments, including divesiran for polycythemia vera, which is in late-stage trials. Silence's shares more than doubled following the announcement. The acquisition strengthens Merck's position in rare diseases and RNA-based therapies.
How this was made
The 30-second read
Why it matters
The deal expands Merck's RNA therapeutic capabilities, potentially accelerating its entry into rare‑disease markets.
Market read
A large‑scale M&A move with immediate price impact and strategic significance for the biotech sector.
What to watch
Regulatory approval timelines for divesiran and other pipeline assets remain uncertain.
Background
Merck continues its strategy of acquiring specialized biotech assets, following prior purchases of SpringWorks and Bio‑Techne.
Ticker impact
Merck announced a $1.3 billion acquisition of Silence Therapeutics, expanding its RNA‑siRNA platform and rare‑disease pipeline.
likely modest upside as market prices in the expanded pipeline and RNA capabilities.
Deal size and premium are material; Merck gains a differentiated technology platform.
Market effects
strengthens the biotech RNA/siRNA sector and may spur further M&A activity.
U.S. biotech market sees heightened interest; European peers may face valuation pressure.
Adds to global competition in rare‑disease therapeutics and RNA drug platforms.
Counterpoint
The premium may be excessive; integration risk could weigh on Merck's margins.
Key entities
- CompanyMerck
Global pharmaceutical group acquiring Silence Therapeutics.
- CompanySilence Therapeutics
Nasdaq‑listed biotech developing siRNA therapies.
